{
    "clinical_study": {
        "@rank": "15011", 
        "arm_group": [
            {
                "arm_group_label": "MSB0010445 (Low Dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MSB0010445 (Intermediate Dose)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MSB0010445 (High Dose)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to\n      assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445\n      given by intravenous infusion to subjects with advanced (unresectable or metastatic)\n      melanoma in combination with stereotactic body radiation therapy (SBRT)."
        }, 
        "brief_title": "MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced unresectable or metastatic melanoma, previously treated with ipilimumab;\n             with at least 1 lesion that can be irradiated; at least 1 measurable lesion outside\n             the radiation field, different from the lesions that will be irradiated; 1 lesion\n             that can be biopsied before treatment with SBRT and MSB0010445; 1 lesion outside the\n             radiation field that can be biopsied while on treatment with MSB0010445; and the\n             lesion that is biopsied at Baseline can be the lesion that will be irradiated\n\n          -  The lesion that will be biopsied while on treatment should not be a lesion that has\n             been irradiated or has been biopsied at Baseline\n\n          -  Signed written informed consent\n\n          -  Male and female subjects at least 18 years of age\n\n          -  Life expectancy greater than or equal to (>=) 4  months\n\n          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Active central nervous system metastasis\n\n          -  Prior treatment with systemic anti-melanoma treatment after ipilimumab treatment\n\n          -  Treatment with ipilimumab within the 30 days before the first dose of SBRT\n\n          -  Concurrent systemic therapy with steroids or other immunosuppressive agents except\n             short-term systemic steroids for allergic reactions\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973608", 
            "org_study_id": "EMR 062235-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSB0010445 (Low Dose)", 
                "description": "MSB0010445 will be administered at a dose of 0.3 mg/kg as intravenous infusion over 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent.", 
                "intervention_name": "MSB0010445 (0.3 milligram per kilogram [mg/kg])", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MSB0010445 (Intermediate Dose)", 
                "description": "MSB0010445 will be administered at a dose of 1.0 mg/kg as intravenous infusion over 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent.", 
                "intervention_name": "MSB0010445 (1.0 mg/kg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MSB0010445 (High Dose)", 
                "description": "MSB0010445 will be administered at a total dose range of 1.8-3.6 mg/kg as intravenous infusion over 1 hour every 3 weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. If the dose of 1.8 mg/kg is not tolerated, then 1.5 mg/kg will be administered.", 
                "intervention_name": "MSB0010445 (1.8-3.6 mg/kg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MSB0010445 (Low Dose)", 
                    "MSB0010445 (Intermediate Dose)", 
                    "MSB0010445 (High Dose)"
                ], 
                "description": "SBRT will be administered at a dose of up to 20 Gray (Gy) on a maximum of 3 lesions or, if the irradiated lesion is located in the thorax, up to 16 Gy. A maximum of 3 SBRT will be administered.", 
                "intervention_name": "Stereotactic Body Radiation Therapy (SBRT)", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Melanoma", 
            "MSB0010445", 
            "Dose limiting toxicity", 
            "Stereotactic body radiation therapy"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "phone": "888-275-7376"
            }, 
            "facility": {
                "address": {
                    "city": "Rockland", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Please Contact U.S. Medical Information Located in"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Dose Limiting Toxicities (DLTs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 25"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973608"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Best Overall Response According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)", 
            "safety_issue": "No", 
            "time_frame": "Screening up to 4 weeks after last dose administration"
        }, 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}